Ontak denileukin diftitox: Phase I/II data; marketed to treat recurrent CTCL

LGND reported that in a U.S. 14-patient Phase I/II study, 8 of 9 evaluable patients with fludarabine-refractory CLL had reductions in peripheral CLL cells after at least 3 courses of Ontak. Two patien...